Tuesday, November 17, 2026
Breaking
Education

Nigeria Pushes For 70% Local Medicine Production

Advertisement

LAGOS, NIGERIA — The World Health Organisation (WHO) and the Nigeria Academy of Pharmacy have called for stronger domestic pharmaceutical manufacturing, increased investment in research and innovation, and improved regulatory systems as Nigeria intensifies efforts to strengthen its health security and reduce dependence on imported medicines.

The call comes as concerns grow over the country’s exposure to disruptions in international medicine supply chains, which can affect the availability, affordability and timely distribution of essential healthcare products.

The position was highlighted during the Nigeria Academy of Pharmacy’s 2026 Annual General Meeting and Investiture of New Fellows in Lagos, where the WHO Representative and Head of Mission in Nigeria, Dr Pavel Ursu, was scheduled to deliver a keynote address on Tuesday, November 17.

The academy, led by its President and Chairman of the Governing Council, Professor Lere Baale, has maintained that Nigeria cannot achieve sustainable health security while relying heavily on foreign suppliers for essential medicines, pharmaceutical technologies and healthcare innovations.

Baale said the country’s health security was inseparable from its economic strength, scientific capacity and national independence. He urged the government to move beyond dependence on imported products by building local expertise, expanding manufacturing capacity and supporting homegrown research.

The academy identified rising healthcare demand, vulnerabilities in medicine supply, emerging infectious diseases and antimicrobial resistance as major reasons Nigeria must strengthen its pharmaceutical sector. It also called for closer collaboration among government agencies, universities, manufacturers, regulatory institutions, healthcare professionals and development partners.

Nigeria’s ambition to produce at least 70 per cent of its essential healthcare products locally by 2030 has become a central part of the Federal Government’s pharmaceutical manufacturing agenda. The Minister of State for Health and Social Welfare, Dr Iziaq Salako, announced the target at the 8th Nigeria Pharma Manufacturers Expo in Lagos in September.

Advertisement

Salako said the Presidential Initiative to Unlock the Healthcare Value Chain had attracted financing commitments of approximately $2 billion at single-digit interest rates, with about 50 Nigerian healthcare companies in advanced discussions for funding. He also disclosed that 87 local manufacturers were benefiting from tariff exemptions covering pharmaceutical machinery, active pharmaceutical ingredients and excipients.

The government has also identified domestic production of vaccines, biologics, diagnostic products and active pharmaceutical ingredients as important areas for expansion. These investments are intended to ensure that local manufacturing goes beyond packaging imported materials and develops capacity across the pharmaceutical value chain.

Regulatory oversight remains another important part of the effort. The National Agency for Food and Drug Administration and Control has been implementing policies designed to encourage domestic production while maintaining medicine quality and safety standards. Its 5+5 policy, introduced to promote local manufacturing of selected medicines, is among the measures intended to reduce import dependence.

However, the scale of the challenge remains significant. A World Health Organisation-supported health-system profile published in 2025 estimated that Nigeria had approximately 150 local pharmaceutical manufacturers, whose combined output met about 30 per cent of the country’s medicine needs. More recent government figures presented in 2026 put the share of locally manufactured medicines in the pharmaceutical market at approximately 50 per cent, indicating reported progress but also the need to clarify the different measures used.

Industry growth will depend on reliable electricity, access to affordable financing, modern production facilities, skilled personnel, research funding and consistent regulatory enforcement. Manufacturers also need dependable demand and a predictable policy environment to justify long-term investments.

The proposed Medipool national group purchasing arrangement is expected to help aggregate demand for essential medicines and create a more predictable market for domestic producers.

Stakeholders are also looking towards regional trade opportunities under the African Continental Free Trade Area, which could allow Nigerian manufacturers to reach larger markets and improve economies of scale.

For the WHO and the Nigeria Academy of Pharmacy, strengthening local pharmaceutical production is not simply an industrial policy objective. It is a critical part of ensuring that Nigerians can access safe, effective and affordable medicines, even when global supply chains come under pressure.

Advertisement
Got News? Report it to DDM. Send a tip